The thesis

Foghorn Therapeutics is a clinical-stage biopharmaceutical company with 112.7% revenue growth. The company's conviction score is 41, indicating a watchlist position. Analysts have a buy consensus rating, despite a -5.3 P/E ratio and -17578% net margin. This setup is interesting due to the disconnect between growth and valuation,

Why now

The current macro context, with the US-China squeeze and Middle East war, may impact investment in biopharmaceuticals. The company's revenue growth and analyst consensus make it a compelling watchlist candidate, especially given the 43-year low in US oil reserves,

What to watch

The company's upcoming financial reports will be crucial in confirming or denying the thesis, particularly the revenue growth and net margin figures. Investors should also watch for updates on the Gene Traffic Control platform and any changes in the analyst consensus rating over the next quarter

Key risks

Valuation risk is a major concern, given the -5.3 P/E ratio and -17578% net margin. Execution risk is also a factor, as the company's Gene Traffic Control platform is still in development. Competitive risk from established biopharmaceutical companies is another potential threat,